98%
921
2 minutes
20
Glioblastoma stem cells (GSC) express both radial glial cell and neural crest cell (NCC)-associated genes. We report that endothelin 3 (EDN3), an essential mitogen for NCC development and migration, is highly produced by GSCs. Serum-induced proliferative differentiation rapidly decreased EDN3 production and downregulated the expression of stemness-associated genes, and reciprocally, two glioblastoma markers, EDN1 and YKL-40 transcripts, were induced. Correspondingly, patient glioblastoma tissues express low levels of EDN3 mRNA and high levels of EDN1 and YKL-40 mRNA. Blocking EDN3/EDN receptor B (EDNRB) signaling by an EDNRB antagonist (BQ788), or EDN3 RNA interference (siRNA), leads to cell apoptosis and functional impairment of tumor sphere formation and cell spreading/migration in culture and loss of tumorigenic capacity in animals. Using exogenous EDN3 as the sole mitogen in culture does not support GSC propagation, but it can rescue GSCs from undergoing cell apoptosis. Molecular analysis by gene expression profiling revealed that most genes downregulated by EDN3/EDNRB blockade were those involved in cytoskeleton organization, pause of growth and differentiation, and DNA damage response, implicating the involvement of EDN3/EDNRB signaling in maintaining GSC migration, undifferentiation, and survival. These data suggest that autocrine EDN3/EDNRB signaling is essential for maintaining GSCs. Incorporating END3/EDNRB-targeted therapies into conventional cancer treatments may have clinical implication for the prevention of tumor recurrence.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3245317 | PMC |
http://dx.doi.org/10.1158/1541-7786.MCR-10-0563 | DOI Listing |
Photodiagnosis Photodyn Ther
September 2025
Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
One of the key factors contributing to the poor prognosis of glioblastoma is the treatment resistance of glioma stem cells (GSCs). In this study, the efficacy of photodynamic therapy (PDT) using talaporfin sodium (NPe6), a second-generation photosensitizer, in combination with a semiconductor laser approved for clinical use in Japan was evaluated. The evaluation was performed in a patient-derived glioma stem cell (GSC) line, MGG8, which was established from human glioblastoma tissue.
View Article and Find Full Text PDFJ Cell Mol Med
September 2025
Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan City, Hubei Province, China.
Glioblastoma (GBM) exhibits remarkable intra-tumoral heterogeneity, which contributes to therapeutic resistance and poor clinical outcomes. In this study, we employed integrative single-cell RNA sequencing analysis across two complementary public datasets encompassing diverse cellular populations from GBM centre and periphery regions to elucidate potential spatial molecular programmes driving tumour progression. Our analyses revealed substantial transcriptomic divergence between anatomically distinct tumour regions, with NUCB2 emerging as significantly upregulated in centre-residing neural progenitor cell-like (NPC-like) tumour cells.
View Article and Find Full Text PDFCurr Mol Med
August 2025
Department of Biochemistry, Dow International Medical College, Dow University of Health Sciences, OJHA Campus, Karachi, Pakistan.
Introduction: Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with a poor prognosis, primarily due to therapy resistance mediated by CD133+ glioblastoma stem cells (GSCs). The BCL3 gene contributes to this resistance and is potentially regulated by Carbonic Anhydrase II (CA II). Additionally, BCL3 enhances β-catenin-mediated transcription, promoting tumor growth.
View Article and Find Full Text PDFCell Res
September 2025
Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.
Tumors evolve to avoid immune destruction and establish an immunosuppressive microenvironment. Syngeneic mouse tumor models are critical for understanding tumor immune evasion and testing cancer immunotherapy. Derived from established mouse tumor cell lines that can already evade the immune system, these models cannot simulate early phases of immunoediting during initial tumorigenesis.
View Article and Find Full Text PDFWorld J Clin Oncol
August 2025
Department of Neurosurgery, University Hospital Marburg, Marburg 35037, Hesse, Germany.
Glioblastoma (GBM) remains a major clinical challenge due to limited therapeutic success despite standard treatments including surgery, radiotherapy, and temozolomide (TMZ). Recent evidence links hyperglycemia to cancer progression, and altered glucose metabolism has emerged as a key factor in GBM development. Metformin, an antidiabetic drug, has shown promise in improving survival in GBM patients, possibly due to its ability to cross the blood-brain barrier and target metabolic pathways involved in tumor growth.
View Article and Find Full Text PDF